The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock increased 4.44% or $0.14 during the last trading session, reaching $3.29. About 781,579 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since June 17, 2018 and is uptrending. It has outperformed by 16.11% the S&P500. Some Historical IFRX News: 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018The move comes after 8 months positive chart setup for the $85.42M company. It was reported on Jun, 17 by Barchart.com. We have $3.42 PT which if reached, will make NASDAQ:IFRX worth $3.42M more.
Among 2 analysts covering Booz Allen Hamilton Holding (NYSE:BAH), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Booz Allen Hamilton Holding had 6 analyst reports since February 20, 2019 according to SRatingsIntel. See Booz Allen Hamilton Holding Corporation (NYSE:BAH) latest ratings:
03/06/2019 Broker: Morgan Stanley Rating: Overweight New Target: $70.0000 Initiates Coverage On
09/05/2019 Broker: Goldman Sachs Rating: Buy New Target: $72.0000 Initiates Coverage On
23/04/2019 Broker: BidaskScore Rating: Hold Downgrade
11/04/2019 Broker: BidaskScore Rating: Buy Downgrade
14/03/2019 Broker: BidaskScore Rating: Buy Upgrade
20/02/2019 Broker: BidaskScore Rating: Buy Downgrade
Since January 31, 2019, it had 0 buys, and 4 insider sales for $5.00 million activity. Shares for $817,500 were sold by Thompson Elizabeth M. ROSSOTTI CHARLES O also sold $532,600 worth of Booz Allen Hamilton Holding Corporation (NYSE:BAH) shares. ROZANSKI HORACIO sold 45,000 shares worth $2.21 million. 27,000 shares were sold by Messer Angela M., worth $1.44 million.
Investors sentiment decreased to 1.03 in Q1 2019. Its down 0.24, from 1.27 in 2018Q4. It dropped, as 35 investors sold Booz Allen Hamilton Holding Corporation shares while 113 reduced holdings. 67 funds opened positions while 85 raised stakes. 123.35 million shares or 1.29% more from 121.78 million shares in 2018Q4 were reported. Balasa Dinverno & Foltz Limited Liability Company holds 4,345 shares or 0.03% of its portfolio. Colorado-based Three Peaks Capital Management Limited Liability Co has invested 0.88% in Booz Allen Hamilton Holding Corporation (NYSE:BAH). First Hawaiian Fincl Bank holds 0.08% or 26,639 shares. Northern has invested 0.02% in Booz Allen Hamilton Holding Corporation (NYSE:BAH). Amer Int Gru reported 0% of its portfolio in Booz Allen Hamilton Holding Corporation (NYSE:BAH). Enterprise Financial reported 32 shares. Pennsylvania Trust Communication owns 19,450 shares. Merian Global Invsts (Uk) has 183,656 shares for 0.1% of their portfolio. Twin Tree Mgmt Ltd Partnership holds 0.05% or 150,258 shares in its portfolio. Boston holds 0.01% or 129,206 shares in its portfolio. Meeder Asset Management holds 0.12% or 27,078 shares. 8,740 are owned by Spectrum Management Grp Inc. Moreover, Opus Cap Gru Ltd Liability Co has 0.32% invested in Booz Allen Hamilton Holding Corporation (NYSE:BAH) for 20,828 shares. Psagot House accumulated 0.05% or 18,800 shares. 1.25 million were accumulated by Robeco Institutional Asset Management Bv.
More notable recent Booz Allen Hamilton Holding Corporation (NYSE:BAH) news were published by: Finance.Yahoo.com which released: “Should You Worry About Booz Allen Hamilton Holding Corporation’s (NYSE:BAH) CEO Pay? – Yahoo Finance” on June 17, 2019, also Finance.Yahoo.com with their article: “Here’s Why I Think Booz Allen Hamilton Holding (NYSE:BAH) Is An Interesting Stock – Yahoo Finance” published on May 31, 2019, Finance.Yahoo.com published: “Booz Allen Hamilton Holding Corp (BAH) Q4 2019 Earnings Call Transcript – Yahoo Finance” on May 28, 2019. More interesting news about Booz Allen Hamilton Holding Corporation (NYSE:BAH) were released by: Benzinga.com and their article: “Morgan Stanley Initiates Coverage On Government Services Stocks – Benzinga” published on June 03, 2019 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Anaplan Jumps Following Upbeat Q1 Results; Kezar Life Sciences Shares Slide – Nasdaq” with publication date: May 28, 2019.
Booz Allen Hamilton Holding Corporation provides management and technology consulting, engineering, analytics, digital, mission operations, and cyber solutions to governments, firms, and not-for-profit organizations in the United States and internationally. The company has market cap of $9.14 billion. The firm offers consulting solutions for various domains, business strategies, human capital, and operations. It has a 22.42 P/E ratio. It also provides analytics services, which focuses on delivering transformational solutions in the areas of decision analytics, including activities research and cost estimation; intelligence analysis, which include source analysis; and tradecraft, data science, and machine intelligence.
The stock increased 0.15% or $0.1 during the last trading session, reaching $65.28. About 194,898 shares traded. Booz Allen Hamilton Holding Corporation (NYSE:BAH) has risen 49.31% since June 17, 2018 and is uptrending. It has outperformed by 44.88% the S&P500. Some Historical BAH News: 29/05/2018 – Booz Allen Hamilton Sees FY Rev Growth 6%-8%; 26/04/2018 – U.S. Air Force Awards Booz Allen Spot on $998M IDIQ Contract to Bolster the 96th Test Wing’s Test Capabilities; 27/03/2018 – BOOZ ALLEN HAMILTON – U.S. EPA AWARDED CO A SPOT ON A $115 MLN, FIVE-YEAR, INDEFINITE DELIVERY/INDEFINITE QUALITY CONTRACT; 29/05/2018 – BOOZ ALLEN HAMILTON – DEPARTMENT OF DEFENSE HAS AWARDED BOOZ ALLEN HAMILTON CONTRACT CARRYING A CEILING VALUE OF $495 MLN; 27/03/2018 – U.S. EPA Awards Booz Allen a Spot on Competitive $115M ITS-BISS III Contract Vehicle to Provide Information Management and; 10/04/2018 – Defense Information Systems Agency Selects Booz Allen for Spot on a $17.5B, 10-Year Contract to Provide Information and; 23/03/2018 – Space and Naval Warfare Systems Center Pacific Awards Booz Allen a Five-Year, $78M Cumulative IDIQ Contract to Provide C4l Solutions; 29/05/2018 – Booz Allen Hamilton 4Q Net $84.9M; 10/05/2018 – BOOZ ALLEN HAMILTON APPOINTS NICHOLAS VEASEY DIRECTOR OF INVESTOR RELATIONS; 06/03/2018 – BOOZ ALLEN HAMILTON – DEPARTMENT OF DEFENSE HAS AWARDED SPOT ON $8.27 BLN JOINT ENTERPRISE RESEARCH DEVELOPMENT, ACQUISITION,PROCUREMENT IDIQ CONTRACT
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $85.42 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.